Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jul;38(7):1462-6.
doi: 10.3899/jrheum.110273.

Serum urate in chronic gout--will it be the first validated soluble biomarker in rheumatology?

Lisa K Stamp  1 , Puja P Khanna, Nicola Dalbeth, Maarten Boers, Walter P Maksymowych, H Ralph Schumacher Jr, Michael A Becker, Patricia A MacDonald, N Lawrence Edwards, Jasvinder A Singh, Lee S Simon, Fiona M McQueen, Tuhina Neogi, Angelo L Gaffo, Vibeke Strand, William J Taylor
Affiliations

Serum urate in chronic gout--will it be the first validated soluble biomarker in rheumatology?

Lisa K Stamp et al. J Rheumatol. 2011 Jul.

Abstract

Objective: To summarize evidence for and endorsement of serum urate (SU) as having fulfilled the OMERACT filter as a soluble biomarker in chronic gout at the 2010 Outcome Measures in Rheumatology Meeting (OMERACT 10).

Methods: Data were presented to support the use of SU as a soluble biomarker in chronic gout and specifically the ability to utilize it to predict future patient-reported outcomes.

Results: SU was accepted as having fulfilled the OMERACT filter by 78% of voters. However, consensus was not obtained regarding its use as a soluble biomarker in chronic gout. Although the majority of the criteria for a soluble biomarker were fulfilled, the key criterion of association of the biomarker with outcomes was not agreed upon. It was agreed that the appropriate choice of endpoint must be linked to its clinical importance to the individual with the disorder and its temporal relationship to the intervention. Appropriate outcomes in chronic gout may therefore include gout flares, reduction in tophi, and patient-reported outcomes.

Conclusion: SU is a critical outcome measure. It has the potential to fulfil criteria for a soluble biomarker. Further analyses of existing data from randomized controlled trials will be required to determine whether SU can predict future important outcomes, in particular disability.

PubMed Disclaimer

References

    1. Taylor W, Schumacher H, Baraf H, Chapman P, Stamp L, Doherty M, et al. A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout. Ann Rheum Dis. 2008;67:888–91. - PubMed
    1. Maksymowych W, Landewe R, Tak P, Ritchlin C, Ostergaard M, Mease P, et al. Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: The OMERACT 9 v2 criteria. J Rheumatol. 2009;36:1785–91. - PubMed
    1. Donnelly J, Soldin S, Nealon D, Hicks J. Stability of twenty-five analytes in human serum at 22 degrees C, 4 degrees C, and −20 degrees C. Pediatr Pathol Lab Med. 1995;15:869–74. - PubMed
    1. DiMagno E, Corle D, O’Brien J, Masnyk I, Go V, Aamodt R. Effect of long-term freezer storage, thawing, and refreezing on selected constituents of serum. Mayo Clin Proc. 1989;64:1226–34. - PubMed
    1. Agamah ES, Srinivasan SR, Webber LS, Berenson GS. Serum uric acid and its relation to cardiovascular disease risk factors in children and young adults from a biracial community: the Bogalusa Heart Study. J Lab Clin Med. 1991;118:241–9. - PubMed

Publication types

LinkOut - more resources